260 results match your criteria: "Cardiovascular Center Frankfurt[Affiliation]"

Background: The Magenta Elevate is a 9-F, self-expanding, catheter-mounted pump delivered sheathed through a commercially available 10-F femoral introducer over the wire to the left ventricle (LV), providing temporary hemodynamic support up to an equivalent of normal cardiac output.

Objectives: The authors sought to assess the feasibility and outcomes of Elevate-supported high-risk percutaneous coronary intervention (HR-PCI) in a first-in-human study and study the hemodynamic impact of high-output support during prolonged interventional left main coronary artery (LM) occlusions.

Methods: In this study, 14 patients underwent Elevate-supported HR-PCI, with 8 patients undergoing 20 prolonged (39 ± 16 seconds) balloon occlusions of an unprotected LM.

View Article and Find Full Text PDF

Background: Covered stent correction for a sinus venosus atrial septal defect (SVASD) was first performed in 2009. This innovative approach was initially viewed as experimental and was reserved for highly selected patients with unusual anatomic variants. In 2016, increasing numbers of procedures began to be performed, and in several centers, it is now offered as a standard of care option alongside surgical repair.

View Article and Find Full Text PDF

Background: Ultrasound renal sympathetic denervation (uRDN) reduces blood pressure (BP) in the absence and presence of antihypertensive treatment at 2 months. Beyond 3 years, there is a lack of follow-up data. This study investigated the long-term safety and efficacy of uRDN.

View Article and Find Full Text PDF

Background: Transcatheter tricuspid valve intervention (TTVI) has been increasingly adopted in recent years for the treatment of patients with tricuspid regurgitation (TR). However, no dedicated risk stratification has been established for patients undergoing TTVI.

Objectives: The aim of the present study was to propose a dedicated risk score for patients affected by severe TR undergoing TTVI.

View Article and Find Full Text PDF
Article Synopsis
  • Percutaneous PFO closure is a common procedure aimed at preventing paradoxic embolism and reducing the risk of stroke in selected patients.
  • Different guidance methods, like transesophageal echocardiography and intracardiac echocardiography, are used during the procedure, each with specific benefits and drawbacks.
  • Transesophageal echocardiography provides detailed imaging but requires additional staff and patient sedation, while intracardiac echocardiography allows a single operator to perform the procedure without needing conscious sedation.
View Article and Find Full Text PDF

Percutaneous LAAO and Pulsed-Field Isolation in a Canine Model: Feasibility and Safety Evaluation.

JACC Basic Transl Sci

August 2024

Department of Arrhythmia, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China.

In this study, we investigated the feasibility, safety, and efficiency of using a novel device system to perform percutaneous left atrial appendage occlusion concomitant with left atrial appendage electrical isolation (LAAEI) via pulsed field ablation. In the acute phase, LAAEI was successful in 10 of 10 canines. At follow-up, full endothelialization was observed in 5 of 5 (100%) cases at 6 months.

View Article and Find Full Text PDF
Article Synopsis
  • Doctors are studying how a procedure called transcatheter tricuspid valve interventions (TTVI) affects patients with heart issues, specifically focusing on something called mitral regurgitation (MR) after the procedure.
  • They looked at data from a big group of patients and found that many showed improvement in MR after the procedure, but some got worse.
  • They discovered that certain factors, like successful procedures and specific treatments, could help predict whether a patient’s MR would improve or get worse after TTVI.
View Article and Find Full Text PDF

Incidence and predictors of 2-year mortality following percutaneous left atrial appendage occlusion in the EWOLUTION trial.

Europace

July 2024

Department of Cardiology, St Antonius Ziekenhuis Nieuwegein/AUMC Amsterdam, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands.

Article Synopsis
  • - Study aimed to determine factors influencing early mortality after left atrial appendage occlusion (LAAO) to improve patient selection and cost-effectiveness for stroke prevention.
  • - Analyzed data from 1,020 patients, finding a 2-year mortality rate of 16.4%, with 50% of deaths attributed to non-cardiovascular causes, and identified six key predictors of mortality including age and heart failure.
  • - Concluded that as the number of risk factors in patients increased, the mortality rate rose significantly, underscoring the need for careful patient selection for LAAO procedures.
View Article and Find Full Text PDF

Introduction: Acute carotid-related stroke (CRS), with its large thrombo-embolic load and large volume of affected brain tissue, poses significant management challenges. First generation (single-layer) carotid stents fail to insulate the athero-thrombotic material; thus they are often non-optimized (increasing thrombosis risk), yet their use is associated with a significant (20-30%) risk of new cerebral embolism.

Aim: To evaluate, in a multi-center multi-specialty investigator-initiated study, outcomes of the MicroNET-covered (cell area ≈ 0.

View Article and Find Full Text PDF
Article Synopsis
  • * It found that patients with mild residual TR had an 85% survival rate, while those with moderate and severe TR had significantly lower rates of 70% and 44%, respectively.
  • * The research emphasizes the need for a more detailed classification of TR severity to better predict patient outcomes and highlights the goal of achieving at least mild to moderate residual TR for successful interventions.
View Article and Find Full Text PDF
Article Synopsis
  • - The study focused on evaluating the safety and effectiveness of the APTURE transcatheter shunt system in patients with heart failure and left ventricular ejection fraction (LVEF) greater than 40%.
  • - Results showed that the APTURE shunt had a low incidence of serious complications (2.6%) and helped improve heart function, as indicated by reduced pulmonary capillary wedge pressure and improved quality of life scores over a year.
  • - Overall, the findings suggest that the APTURE shunt is a promising option for managing heart failure in patients with mildly reduced or preserved ejection fraction.
View Article and Find Full Text PDF
Article Synopsis
  • The study examines the effectiveness of the TRI-SCORE in predicting outcomes for patients undergoing transcatheter tricuspid valve intervention (TTVI), using data from a large, international registry called TriValve.
  • Among the 634 patients analyzed, those with a TRI-SCORE of 8 or higher were found to have a significantly increased risk of all-cause mortality and complications within 30 days of the procedure, compared to those with lower TRI-SCOREs.
  • Despite indicating a higher risk for severe outcomes, the TRI-SCORE overall showed limited effectiveness in predicting clinical results following TTVI, as improvements in patient functional class were observed across all TRI-SCORE levels.
View Article and Find Full Text PDF

Aims: T-TEER is an effective therapy for the treatment of tricuspid regurgitation (TR). However, the effects of leaflets clipping on tricuspid valve annulus (TA) have not been investigated in detail. The aim of this study is to investigate the effects of tricuspid transcatheter edge-to-edge repair (T-TEER) on TA diameter.

View Article and Find Full Text PDF

World Federation for Interventional Stroke Treatment (WIST) multispecialty training guidelines for endovascular stroke intervention: Time is brain! - Response to commentary by UKNG.

Clin Radiol

April 2024

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; Gates Vascular Institute at Kaleida Health, Buffalo, NY, USA; Canon Stroke and Vascular Research Center, University at Buffalo, Buffalo, NY, USA; Jacobs Institute, Buffalo, NY, USA.

View Article and Find Full Text PDF

Persistent and Recurrent Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes.

JACC Cardiovasc Interv

November 2023

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada; Department of Cardiology, Hospital Clínic of Barcelona, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain. Electronic address:

Article Synopsis
  • This study investigates device-related thrombus (DRT) occurrences after left atrial appendage closure (LAAC), focusing on how often it persists or recurs.
  • It found that about 29% of DRT cases persist, with being female and having a larger initial thrombus size being significant predictors.
  • Unfavorable DRT evolution is linked to a higher rate of thromboembolic events, emphasizing the importance of monitoring thrombus size post-LAAC.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to compare the characteristics and outcomes of patients with atrial STR (ASTR) and ventricular STR (VSTR) who underwent transcatheter edge-to-edge repair (T-TEER) for tricuspid regurgitation (TR).
  • Patients were categorized into ASTR or VSTR based on specific cardiac criteria, and a total of 298 were included in the analysis, with similar procedural success rates for both groups.
  • Results showed that while T-TEER effectively reduced TR in both ASTR and VSTR patients, survival rates at 12 months were significantly higher for ASTR (91%) compared to VSTR (72%).
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the potential impact of the atrial flow regulator (AFR) device on the survival rates of patients with heart failure, both with reduced and preserved ejection fractions.
  • In a multicenter study of 87 patients with symptomatic heart failure, the observed mortality rate was 7%, while the predicted mortality rate was significantly higher at 12.2 deaths per 100 patient-years.
  • Results indicated that patients with heart failure and preserved ejection fraction had a significantly lower observed mortality rate compared to their predicted rate, while there was no significant difference for those with heart failure and reduced ejection fraction.
View Article and Find Full Text PDF
Article Synopsis
  • - The study explores a new transcatheter device called the Vsling, designed to reshape the dilated left ventricle in patients with systolic heart failure, offering a potentially better alternative to current treatments.
  • - Trials showed that the Vsling was successfully implanted in a series of tests, including chronic animal models and a human cadaver, with positive feedback from interventional cardiologists regarding its usability.
  • - Results indicated that the device had good safety, showing minimal inflammation and no serious adverse reactions over 90 days, leading to plans for human trials starting in summer 2022.
View Article and Find Full Text PDF

Background: Endovascular baroreflex amplification with the MobiusHD, a self-expanding stent-like device that is implanted in the internal carotid artery, was designed to reduce the sympathetic overactivity that contributes to progressive heart failure with reduced ejection fraction.

Methods: Symptomatic patients (New York Heart Association class III) with heart failure with reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤40%) despite guideline directed medical therapy and n-terminal pro-B type natriuretic peptide (NT-proBNP) levels ≥400 pg/mL in whom carotid ultrasound and computed tomographic angiography demonstrated absence of carotid plaque were enrolled. Baseline and follow-up measures included 6-minute walk distance (6MWD), Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ OSS), and repeat biomarkers and transthoracic echocardiography.

View Article and Find Full Text PDF

Transcatheter Aortic Valve Replacement Outcomes in End-Stage Renal Disease Patients on Hemodialysis Requiring Midodrine.

Struct Heart

May 2023

Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, Oregon, USA.

Background: Patients with dialysis-dependent end-stage renal disease (ESRD) taking midodrine may be at high risk for poor outcomes following transcatheter aortic valve replacement (TAVR). We evaluated dialysis-dependent ESRD patients taking midodrine.

Methods: We conducted a retrospective analysis of non-clinical trial TAVR patients from February 2012 to December 2020 from 11 facilities in a Western US health system.

View Article and Find Full Text PDF

Clinical and economic burdens exist within the coronary artery disease (CAD) care pathway despite advances in diagnosis and treatment and the increasing utilization of percutaneous coronary intervention (PCI). However, research presenting a comprehensive assessment of the challenges across this pathway is scarce. This contemporary review identifies relevant studies related to inefficiencies in the diagnosis, treatment, and management of CAD, including clinician, patient, and economic burdens.

View Article and Find Full Text PDF

Aims: In heart failure (HF), implantable haemodynamic monitoring devices have been shown to optimize therapy, anticipating clinical decompensation and preventing hospitalization. Direct left-sided haemodynamic sensors offer theoretical benefits beyond pulmonary artery pressure monitoring systems. We evaluated the safety, usability, and performance of a novel left atrial pressure (LAP) monitoring system in HF patients.

View Article and Find Full Text PDF